Litcius/Paper detail

Resveratrol-zinc nanoparticles or pterostilbene-zinc: Potential COVID-19 mono and adjuvant therapy

Mina Kelleni

2021Biomedicine & Pharmacotherapy42 citationsDOIOpen Access PDF

Abstract

In this manuscript we provide the scientific basis to adopt a novel combination of two widely available nutraceuticals; resveratrol and zinc in management of COVID-19 recommending their administration using a nano-carrier based drug-delivery system. Resveratrol, a well-known antioxidant and anti-inflammatory triphenolic stilbene, is abundant in red grapes, red wine, dark chocolate, and peanut butter. Alternatively, pterostilbene-zinc combination might be also considered without using a nano-carrier. We recommend conducting prompt clinical trials to assess the potential of the suggested combinations as a monotherapy for mild COVID-19 with a potential to prevent its progression to moderate-severe disease for which we recommend their trial as an adjuvant therapy. Furthermore, the suggested combinations might also possess a pharmacotherapeutic potential that exceeds COVID-19 to various inflammatory, immunologic, and oncologic diseases.

Topics & Concepts

PterostilbeneResveratrolMedicineAdjuvantNutraceuticalCoronavirus disease 2019 (COVID-19)PharmacologyAdjuvant therapyZincDrugClinical trialDiseaseImmunologyInternal medicineChemistryCancerPathologyOrganic chemistryInfectious disease (medical specialty)Sirtuins and Resveratrol in MedicineCOVID-19 Clinical Research StudiesSARS-CoV-2 and COVID-19 Research